Pfizer/BioNTech New COVID Shot Endorsed by EMA Advisory Panel
BioNTech SE's (NASDAQ:BNTX) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
BioNTech's Omicron Vaccine Awaits EU Approval
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
This week's hot US stocks | Chinese concept stocks surge! Li Auto Inc and jd.com lead the way; with the Federal Reserve interest rate cut implemented, the financial crediting sector benefits and rises.
usa's used car dealer Carvana has risen for four consecutive days this week, with a cumulative increase of over 20%, also setting a new high for the year, with a total increase of 222.5% this year.
BioNTech Price Target Raised to $150.00/Share From $95.00 by Deutsche Bank
BioNTech Is Maintained at Buy by Deutsche Bank
Watching BioNTech; Traders Circulating Stock Picked By Popular Retail Trading Newsletter
US stocks mining | The Federal Reserve cuts interest rates more than expected! Multiple real estate-related stocks reach new highs for the year; Accelerate the acquisition plan, US private equity giant KKR rises more than 9% in five days
Soft landing expected to ignite! ai optical communication company Coherent rose nearly 4% on the previous trading day, with a cumulative increase of nearly 90% within the year; ai cloud computing service platform servicenow hit another historical high intraday, with a total annual increase of over 26%.
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Raises Target Price to $150
Deutsche Bank analyst Emmanuel Papadakis maintains $BioNTech(BNTX.US)$ with a buy rating, and adjusts the target price from $95 to $150.According to TipRanks data, the analyst has a success rate of 56
Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 6.93 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 18, $BioNTech(BNTX.US)$ 10% Stockholder ATHOS KG intends to sell 55,605 shares of its common stock on Sep 18, with a total market value of approximately $6.93 million.
UBS Maintains BioNTech(BNTX.US) With Hold Rating, Raises Target Price to $131
UBS analyst Eliana Merle maintains $BioNTech(BNTX.US)$ with a hold rating, and adjusts the target price from $101 to $131.According to TipRanks data, the analyst has a success rate of 38.9% and a
Apple, Biontech, ResMed Among Morning Market Cap Stock Movers on Wednesday
UBS Maintains Neutral on BioNTech, Raises Price Target to $131
Form 144 | BioNTech(BNTX.US) 10% Stockholder Proposes to Sell 3.75 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 17, $BioNTech(BNTX.US)$ 10% Stockholder ATHOS KG intends to sell 30,162 shares of its common stock on Sep 17, with a total market value of approximately $3.75 million.
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
US stocks are moving: BioNTech rose about 6.5% at one point and will hold AI Day event in London on October 1st.
On September 17th, BioNTech SE (BNTX.US) rose by about 6.5% to a high of $131.49. On the news front, BioNTech SE and its artificial intelligence company InstaDeep will host the BioNTech 'Innovation Series' AI Day in London, United Kingdom, at 9 a.m. EDT on October 1st. The event will outline BioNTech and InstaDeep's artificial intelligence strategy and capabilities, as well as the application of artificial intelligence in BioNTech's pipeline and internal processes. In addition, several Wall Street
BioNTech Price Target Raised to $150.00/Share From $96.00 by Jefferies
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $125 to $171
On Sep 17, major Wall Street analysts update their ratings for $BioNTech(BNTX.US)$, with price targets ranging from $125 to $171.J.P. Morgan analyst Jessica Fye upgrades to a hold rating, and sets
BioNTech Analyst Ratings